MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New target identified for squamous cell lung cancer

Back to lung cancer blog Blogs list Cancer blog  


Subscribe To Lung Cancer Blog RSS Feed  RSS content feed What is RSS feed?

New target identified for squamous cell lung cancer




Researchers at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

The findings appear in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, from April 2-6.

As per lead researcher Matthew Meyerson, M.D., Ph.D., professor of pathology at the Dana Farber Cancer Institute, there are currently no targeted therapies for squamous cell lung cancer, which affects approximately 50,000 people annually in the United States. Meyerson estimates that DDR2 mutations would be present in lung cancers from about one to two thousand people a year in the United States.



New target identified for squamous cell lung cancer

"As a percentage of the millions of people who get cancer each year it is small, but cancer treatment is going more in the direction of personalized medicine as we learn more and more about the complicated biology of each tumor," he said.

Using standard genetic sequencing techniques, Meyerson and his colleagues identified mutations in the DDR2 kinase gene in about 3 percent of squamous cell lung cancers and cell lines. Furthermore, they observed that tumor cells with these DDR2 mutations responded to therapy with dasatinib. A patient whose cancer carried a DDR2 mutation also showed a clinical response to dasatinib.

"Dasatinib is an existing treatment for chronic myelogenous leukemia with a long history and a strong safety profile," said Meyerson. "The results of this study clearly encourage a clinical trial to test dasatinib in the setting of squamous cell lung cancer."


Posted by: Scott    Source




Did you know?
Researchers at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib. The findings appear in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, from April 2-6.

Medicineworld.org: New target identified for squamous cell lung cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.